Javascript must be enabled to continue!
LC-MS characterization of valsartan degradation products and comparison with LC-PDA
View through CrossRef
abstract Valsartan was submitted to forced degradation under acid hydrolysis condition as prescribed by the ICH. Degraded sample aliquots were separated via HPLC using a Hypersil ODS (C18) column (250 x 4.6 mm i.d., 5 µm). Either photodiode array (PDA) detection or mass spectrometry (MS) full scan monitoring of HPLC runs were used. HPLC-PDA failed to indicate Valsartan degradation under forced acid degradation, showing an insignificant peak area variation and that Valsartan apparently remained pure. HPLC-MS using electrospray ionization (ESI) and total ionic current (TIC) monitoring did not reveal any peak variation either, but inspection of the ESI mass spectra showed the appearance of m/z 306 and m/z 352 ions for the same retention time as that of Valsartan (m/z 436). These ions were identified as being protonated molecules of two co-eluting degradation products formed by hydrolysis. These assignments were confirmed by ESI-MS/MS with direct infusion of the degraded samples. The results showed that the use of selective HPLC-MS is essential for monitoring Valsartan degradation. Efficient HPLC separation coupled to selective and structural diagnostic MS monitoring seems therefore mandatory for comprehensive drug degradation studies, particularly for new drugs and formulations, and for method development.
Title: LC-MS characterization of valsartan degradation products and comparison with LC-PDA
Description:
abstract Valsartan was submitted to forced degradation under acid hydrolysis condition as prescribed by the ICH.
Degraded sample aliquots were separated via HPLC using a Hypersil ODS (C18) column (250 x 4.
6 mm i.
d.
, 5 µm).
Either photodiode array (PDA) detection or mass spectrometry (MS) full scan monitoring of HPLC runs were used.
HPLC-PDA failed to indicate Valsartan degradation under forced acid degradation, showing an insignificant peak area variation and that Valsartan apparently remained pure.
HPLC-MS using electrospray ionization (ESI) and total ionic current (TIC) monitoring did not reveal any peak variation either, but inspection of the ESI mass spectra showed the appearance of m/z 306 and m/z 352 ions for the same retention time as that of Valsartan (m/z 436).
These ions were identified as being protonated molecules of two co-eluting degradation products formed by hydrolysis.
These assignments were confirmed by ESI-MS/MS with direct infusion of the degraded samples.
The results showed that the use of selective HPLC-MS is essential for monitoring Valsartan degradation.
Efficient HPLC separation coupled to selective and structural diagnostic MS monitoring seems therefore mandatory for comprehensive drug degradation studies, particularly for new drugs and formulations, and for method development.
Related Results
Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial
Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial
Abstract
Background
In the VICTORIA trial (n=5050) the reduction in the primary composite endpoint of cardiovascular death (CVD)...
Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
The development and progression of heart failure (HF) due to myocardial infarction (MI) is a major concern even with current optimal therapy. Resveratrol is a plant polyphenol with...
Pengaruh Valsartan Terhadap Fibrosis Ginjal pada Obstruksi Ureter
Pengaruh Valsartan Terhadap Fibrosis Ginjal pada Obstruksi Ureter
AbstrakPendahuluan : Obstruksi ureter merupakan kondisi yang dapat terjadi pada setiap usia dengan levelbervariasi dengan efek terburuk berupa gagal ginjal permanen. Terdapat berba...
The development of a novel universal coating for urological implants
The development of a novel universal coating for urological implants
Urology employs various implants, such as urinary catheters, ureteral stents, and ureteral access sheaths (UASs), to manage diseases associated with the urinary tract system. These...
Patent Ductus Arteriosus Response to Treatment by Course and Associations with Perinatal and Clinical Factors
Patent Ductus Arteriosus Response to Treatment by Course and Associations with Perinatal and Clinical Factors
Objective The objective of this study is to examine patent ductus arteriosus (PDA) response by treatment course and investigate associations with postmenstrual age (PMA), chronolog...
The impact of Valsartan on vascular endothelial cells in plaque with ApoE knockout mice
The impact of Valsartan on vascular endothelial cells in plaque with ApoE knockout mice
Background
To investigate whether Valsartan plays a role in vascular endothelial cells in plaque and hs-CRP with ApoE knockout mice, thus improving plaque stabili...
Matériaux composites 2D à base d'oxyde de graphène réduit et de polydopamine pour supercondensateurs : développement, propriétés interfaciales et micro-dispositifs
Matériaux composites 2D à base d'oxyde de graphène réduit et de polydopamine pour supercondensateurs : développement, propriétés interfaciales et micro-dispositifs
L’objectif de cette thèse est la synthèse et l'optimisation de nouveaux matériaux composites à base d'oxyde de graphène réduit (rGO) et de polydopamine comme électrodes prometteuse...
Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study
Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study
Abstract:
Nitrosamine contamination of generic valsartan was found in 2018. This study aimed to investigate whether long-term use of valsartan increases cancer risk. Pati...

